Recently, the FOXG1 Research Foundation announced that its treatment forFOXG1 SyndromeThe AAV gene therapy FRF-001 (AAV9-FOXG1) under research has received approval from the U.S. FDA for a new drug clinical trial application (IND). This milestone not only marks the upcoming entry of this innovative therapy into the clinical trial phase but also highlights the importance of foundations initiated by patient organizations in actively exploring models for the development of orphan drugs.

Recently, Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Nanoscope's lead asset MCO-010 the designation of Advanced Therapy Medicinal Product and Orphan Drug for the treatment of severe vision loss in patients with inherited retinal diseases (IRD).

MCO is a one-time, in-office, intravitreal injection treatment platform for multiple retinal diseases, designed to restore vision in patients with photoreceptor degeneration, including Retinitis Pigmentosa (RP), Stargardt Disease (SD), and Geographic Atrophy (GA). MCO works by activating high-density bipolar retinal cells to make them light-sensitive, thereby utilizing the remaining visual circuitry after photoreceptor death. MCO treatment does not require genetic testing, invasive surgery, or repeated dosing, making it widely applicable within existing retinal diagnosis and treatment workflows.

Recently, the field of ophthalmic gene therapy has received double good news. OCU410, an innovative modified gene therapy developed by Ocugen, has achieved breakthrough results in two clinical trials for different indications. The therapy targets two currently untreatable blinding diseases—hereditary Stargardt disease and the advanced stage of geographic atrophy in dry age-related macular degeneration—demonstrating significant lesion control and vision protection effects.

OCU410 represents a completely new therapeutic strategy: delivering the RORA gene to the retina via an adeno-associated viral vector to restore the function of this nuclear hormone receptor, thereby regulating the disease process through multiple pathways, including reducing lipofuscin accumulation, alleviating oxidative stress, suppressing inflammatory responses, and modulating the complement system.

Recommended Reading：Major Breakthrough in Ophthalmic Gene Therapy: Two Birds with One Stone, Single Treatment to Combat Two Blinding Eye Diseases Simultaneously

GENE202 is an off-the-shelf in vivo gene therapy developed based on the Immune-Shielded Lentiviral Vector (ISLV) platform. The therapy is administered intravenously to deliver a healthy copy of the MMUT gene to the patient's liver cells, enabling the liver to continuously express the functional MMUT enzyme required to restore the blocked metabolic pathway and prevent the accumulation of toxic substances. Genespire's proprietary vector shielding technology helps prevent the therapy from being recognized by the human immune system, potentially enhancing the safety and efficacy of the treatment.

Recommended Reading:Another Gene Therapy for Rare Diseases Granted FDA and EU Orphan Drug Designation!

2026On January 19, a research team led by Wang Dan from the University of Massachusetts published an article titled "An engineered UGA suppressor tRNA gene for disease-agnostic AAV delivery" in Nature Biotechnology. The research team successfully achieved efficient rAAV packaging of UGA-sup-tRNA by optimizing the tRNA expression cassette, developing a CuO-CymR-based transcription silencing system, and screening out a highly efficient rAAV production cell line. This therapy restored approximately 10% enzyme activity with a single dose in two mouse models of lysosomal storage diseases, revealing that its superior efficacy in muscle tissue is related to tRNA abundance and aminoacylation efficiency. This breakthrough not only provides the first scalable gene therapy solution for rare diseases associated with UGA nonsense mutations but also validates a universal therapeutic paradigm of "one tRNA reading through multiple diseases," offering significant insights for accelerating rare disease drug development and reducing R&D costs.

Recommended Reading:Nat. Biotechnol | One Injection for Multiple Rare Diseases? Wang Dan's Team Develops CuO-CymR Silencing System to Solve the Problem of sup-tRNA Inhibiting rAAV Production

2026 On January 22, Cancer Cell journal published two CAR-T cell therapy research papers back-to-back. Both studies developed CAR-T cell therapies targeting tumor-associated macrophages (TAM) expressing IL-12. By targeting and eliminating immunosuppressive tumor-associated macrophages, these therapies reshape the tumor microenvironment and stimulate anti-tumor immune responses against solid tumors, demonstrating potential as a universal, tumor antigen-independent CAR-T cell therapy for solid tumors.

Recommended Reading:Back-to-Back Two Articles in Cancer Cell: CAR-T Cell Therapy Targeting Macrophages, Remodeling the Tumor Microenvironment, Broad-Spectrum Treatment of Solid Tumors